MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Logarithmic IMPACT
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

TransPerfect and Sentrx Partner to Offer Pharmacovigilance Safety Solution - TransPerfect & Sentrx announced a collaboration involving TransPerfect’s Trial Interactive Portal Technology to streamline end-to-end global drug safety capabilities in both clinical & post-marketing event management - Sentrx.com
TransPerfect and Sentrx Partner to Offer Pharmacovigilance Safety Solution

 

NewswireToday - /newswire/ - Little Falls, NJ, United States, 2011/06/20 - TransPerfect & Sentrx announced a collaboration involving TransPerfect’s Trial Interactive Portal Technology to streamline end-to-end global drug safety capabilities in both clinical & post-marketing event management - Sentrx.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

TransPerfect and Sentrx have announced a collaboration involving TransPerfect’s Trial Interactive Portal Technology, which will streamline end-to-end global drug safety capabilities in both clinical and post-marketing event management. Trial Interactive, already widely used throughout the biopharmaceutical industry for electronic Trial Master Files, investigator portals, IRB, and central laboratory solutions, collaborated with Sentrx to develop a novel safety module that is fully validated to be 21 CFR Part 11 compliant.

The Trial Interactive Portal Solution will enable direct safety information collection on a global basis from investigative site personnel via multiple sources, including fax, E:, direct-entry, or by telephonic means, into a secure data portal. The approach will speed safety data exchange between safety teams and reporters while enhancing sponsors’ ability to support multiple stakeholders globally. The portal is fully compatible with Sentrx’s industry leading drug safety solution, SaPh™ which provides turnkey Argus Safety instance management in a hassle-free, hosted deployment.

According to Michael O’Gorman, President and General Manager of Sentrx,“Web based portal solutions have been identified as a critical imperative for achieving new gains in adverse event management efficiency. Our collaboration with Trial Interactive has produced a fully compliant safety portal platform to enhance workflow efficiency. We believe this is a breakthrough approach our respective client base will find compelling under a wide variety of applications.”

Michael Smyth, General Manager of TransPerfect’s Life Sciences Solutions division commented,“Working with Sentrx continues with our vision of offering end-to-end technology and service solutions to all study stakeholders, particularly investigative site personnel who are critical in the process of getting products to market faster. The addition of the safety module in Trial Interactive, developed with Sentrx, provides the ability to truly offer global Pharmacovigilance support to pharmaceutical, biotechnology, and medical device companies as well as CROs.”

About Sentrx

We are drug safety experts. Our highly experienced teams focus in safety technology systems, adverse event management and medical affairs. Sentrx solutions (sentrx.com) include SaPh™, CROPlus™ and UniPhi™ and are customized, integrated and scalable to enhance efficiency, reduce cost, and improve flexibility. Our experience is unmatched, built over 15 years serving a broad range of bio-pharmaceutical clients, including CROs.

About TransPerfect Life Sciences Solutions

TransPerfect Life Sciences Solutions (trialinteractive.com) provides leading web-based platforms that enable sponsors, CROs, IRBs, central laboratories and other vendors to complete, maintain and update clinical trial documentation in a secure online collaborative environment, enabling fully searchable solutions including investigator portals and eTMFs. TransPerfect’s solutions streamline study timelines and reduce the administrative burdens of a clinical trial on a global basis. For more information on Trial Interactive or TransPerfect Life Sciences Solutions, please contact info[.]trialinteractive.com or +1 212.400.8848, or visit the website.

About TransPerfect

With revenue of over $250 million, TransPerfect (transperfect.com) is the largest privately held language services provider in the world. From offices in 66 cities on 5 continents, TransPerfect offers a full range of services in over 100 languages to multinationals worldwide. With a global network of over 4,000 linguists and subject-area specialists, TransPerfect is the largest translation company to be fully ISO 9001:2008 and EN 15038:2006 certified. TransPerfect is headquartered in New York and has regional headquarters in London and Hong Kong.

For information contact:
Michael Smyth - General Manager, Life Sciences Solutions TransPerfect
P: +1 212.689.5555 / E: msmyth[.]transperfect.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Logarithmic IMPACT

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


TransPerfect and Sentrx Partner to Offer Pharmacovigilance Safety Solution

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Michael O'Gorman - Sentrx.com 
973-826-1815 info[.]sentrx.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Logarithmic IMPACT securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Logarithmic IMPACT / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research
Global Bio-Based Chemicals Market Projected to Grow At a CAGR of 16.67% by 2027 Finds Inkwood Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)